Psilocybin and SSRIs: Will Antidepressants Block the Effect?

Psilocybin Drug Interactions

47% of SSRI reports described weaker-than-expected psilocybin effects

A 2023 retrospective survey of 611 co-use reports found weaker effects in 47% of SSRI reports and 55% of SNRI reports — but only 29% for bupropion, which does not act mainly on serotonin. The blunting may persist for months after stopping.

Gukasyan et al., Journal of Psychopharmacology, 2023

29%

blunting on bupropion — the non-serotonergic comparator that points at the mechanism (Gukasyan 2023)

3–6 months

before the blunting rate dropped significantly after stopping an SSRI (Gukasyan 2023)

19 patients

kept on their SSRI in an open-label trial still improved on MADRS (Goodwin 2023)

Gukasyan et al., Journal of Psychopharmacology, 2023

View as image ↗

If you are on antidepressants and researching psilocybin, the evidence points to something more specific than "it won't work." SSRIs and SNRIs appear to weaken psilocybin's effects in a large minority to a slight majority of people, and the effect on the experience is much better documented than any effect on danger. In a 2023 retrospective survey, 47% of reports involving an SSRI described weaker-than-expected effects, as did 55% of SNRI reports.^[1] A small 2023 open-label trial found that patients who stayed on their SSRI still improved on a standard depression scale after a single psilocybin dose.^[2]

The safety question has a different shape. A 2024 systematic review of drug interactions across the classic psychedelics reported that, apart from a small number of case reports, no serious adverse drug events were described in the studies it included.^[3] That is genuinely reassuring, and it is also a statement about a thin evidence base rather than a clean bill of health — a point this article returns to, because a separate analysis of real-world reports did surface a small serotonin-toxicity signal.^[4]

So the honest summary is narrower than the usual one: for SSRIs and SNRIs the dominant, best-evidenced problem is reduced effect, not acute harm. That is not the same as saying the combination is proven safe. For broader context, see the complete guide to psilocybin safety. Nothing here is medical advice, and no part of it is a reason to change a prescription on your own.

What the Survey Actually Found — and Who Ran It

The most-cited evidence on this question is a 2023 retrospective online survey by Gukasyan and colleagues, published in the Journal of Psychopharmacology.^[1] It is worth naming the authors correctly, because this study is frequently misattributed in secondary coverage.

The design was straightforward. Researchers surveyed people who had used psilocybin mushrooms either while taking an antidepressant, or within two years of stopping one. To make the comparison meaningful, participants who took mushrooms with an antidepressant only counted if they could anchor the experience against something — either the same dose taken before starting the antidepressant, or the same dose taken alongside other people who were not on one. They then reported the strength of the drug effect relative to what they expected.

Across 611 such reports, the probability of weaker-than-expected effects was 0.47 (95% CI 0.41–0.54) for SSRIs and 0.55 (95% CI 0.44–0.67) for SNRIs. For bupropion, it was 0.29 (95% CI 0.20–0.39).

Blunting Probability, by Antidepressant Class

It Is Not One Number — and Bupropion Is the Control That Proves It

Probability that psilocybin felt weaker than expected when taken alongside an antidepressant, across 611 retrospective reports. Bars show the point estimate; the thin line is the 95% confidence interval. Bupropion — which does not act mainly on serotonin — is the internal comparison that makes the serotonergic pattern interpretable.

The confidence intervals for SSRIs and SNRIs overlap, so this data does not establish that SNRIs blunt more than SSRIs. What it does show is that both serotonergic classes sit near or above a coin flip, while the non-serotonergic comparator sits well below one — which is the finding that points at serotonin signalling rather than at antidepressants in general.

Source: Gukasyan et al. (2023), Journal of Psychopharmacology 37(7):707–716 (RTHM-01703). Retrospective online survey, n = 611 antidepressant co-use reports; self-reported doses were not independently verified.

The bupropion number is the most useful thing in the study and the most frequently dropped. Bupropion is an antidepressant that works mainly on dopamine and norepinephrine rather than serotonin. If psilocybin were simply blunted by "being on an antidepressant," bupropion should blunt it about as often. It blunted it noticeably less. That internal comparison is what elevates this from an anecdote pile to something that actually implicates serotonin signalling.

The limitations are real and the authors do not hide them. These are retrospective self-reports with no verification of what was actually consumed or at what dose — mushroom potency varies substantially between and within batches. People with dramatic experiences in either direction may be likelier to respond. And expectation itself is a live confounder: someone who has read that SSRIs blunt psilocybin may be primed to notice blunting.

Primary Evidence

Gukasyan, Griffiths, Yaden, Antoine & Nayak (2023) · Journal of Psychopharmacology

Population

611 reports of psilocybin mushroom use alongside an antidepressant; 1,542 reports following antidepressant discontinuation

Intervention

Retrospective online survey of self-reported psilocybin mushroom experiences

Comparator

Bupropion (non-serotonergic antidepressant), plus each participant's own anchor dose

Finding

Weaker-than-expected effects in 47% of SSRI reports and 55% of SNRI reports, versus 29% for bupropion. Reduced effects persisted after discontinuation, with no significant drop until the 3–6 month window.

preliminary Retrospective, self-reported, and unverified for dose or product identity. Strong enough to establish that the interaction is real and common; not strong enough to quantify how much effect is lost.

Gukasyan et al. (2023), J Psychopharmacol 37(7):707–716 (RTHM-01703)

The 3-Month Problem: Why Stopping May Not Be Enough

The same survey produced a second finding that matters more clinically and travels less widely.

Among 1,542 reports from people who had already discontinued an SSRI or SNRI, the probability of reduced psilocybin effects was not significantly different from the earliest post-discontinuation timepoint — within one week of stopping — until the 3–6 month window, where it fell to 0.30 (95% CI 0.20–0.46, p = 0.001).^[1]

Read that carefully, because it is easy to overstate. The study did not show that blunting is constant for three months and then switches off. It showed that this dataset could not detect a reduction in blunting until that far out. A gradual recovery would be hard for a retrospective survey to resolve. What the data does rule out is the comfortable assumption that a couple of weeks resets you.

Washout Advice vs. Measured Recovery

The Gap Between When the Drug Leaves and When the Effect Comes Back

Across 1,542 reports from people who had already stopped their antidepressant, the rate of blunted psilocybin effects stayed statistically indistinguishable from the within-one-week rate all the way out to the 3–6 month window. The conventional pre-session washout ends long before that.

Two cautions on reading this. First, “not significantly different” is not the same as “unchanged” — it means this dataset could not resolve a difference, and retrospective self-reports are a weak instrument for detecting a gradual slope. Second, the authors re-ran the analysis without fluoxetine, the SSRI with an unusually long half-life, and the result held — so the persistence is unlikely to be explained by leftover drug alone.

Measured values: Gukasyan et al. (2023), Journal of Psychopharmacology 37(7):707–716 (RTHM-01703), n = 1,542 post-discontinuation reports. The 2–4 week band reflects conventional pre-session guidance and is shown for comparison, not as a finding of that study. Not medical advice.

The authors anticipated the obvious objection — that this is just slow drug clearance — and tested it. Fluoxetine has an unusually long half-life among SSRIs, so if residual drug explained the persistence, removing fluoxetine responses should shrink the effect. It did not significantly alter the result.^[1] That is a meaningful piece of internal evidence that something slower than pharmacokinetics is involved.

This is why the conventional washout advice sits awkwardly against the data. A 2–4 week window is built around clearing the drug. If the relevant variable is an adaptation the brain made over months or years of exposure, clearance is the wrong clock to be reading.

Fact Check

'SSRIs block psilocybin, so there's no point'

The claim

“SSRIs block psilocybin entirely, so taking it while on antidepressants is pointless.”

A compression of the survey headline — '50% report weaker effects' gets rounded up to 'it doesn't work.'

What research shows

Overstated

Blunting is common but far from universal. In the Reddit content analysis, 39% of co-use reports described unchanged intensity. In the open-label trial, 19 patients who stayed on their SSRI still showed a mean 14.9-point MADRS improvement at three weeks, with response and remission each in 42.1% of participants.

'Not blocked' is not the same as 'unaffected.' The trial had no comparison group, so it cannot tell you how much larger the benefit might have been off the SSRI — and the survey suggests roughly half of people will notice a weaker experience.

Gukasyan et al. (2023) RTHM-01703; Goodwin et al. (2023) RTHM-01698; Sakai et al. (2024) RTHM-01979

The Trial That Kept Patients on Their SSRIs

The most directly relevant clinical evidence is a 2023 study by Goodwin and colleagues in Neuropsychopharmacology.^[2] (It is often cited under the wrong lead author and the wrong journal name; the journal is Neuropsychopharmacology, published for the American College of Neuropsychopharmacology.)

Withdrawing from serotonergic antidepressants has been a standard entry requirement for psilocybin trials, precisely because of the interaction this article is about. That requirement excludes many of the patients most likely to be offered psilocybin therapy. This phase II, exploratory, international, fixed-dose, open-label study asked what happens if you simply do not withdraw them.

Nineteen participants with treatment-resistant depression stayed on their SSRI and received a single 25 mg dose of synthetic psilocybin (COMP360) alongside psychological support, then were followed for three weeks. Mean baseline MADRS score was 31.7 (SD 5.77). At week 3, the mean change from baseline was −14.9 points (95% CI −20.7 to −9.2). Response and remission were each observed in 8 of 19 participants (42.1%). Twelve participants (63.2%) had a treatment-emergent adverse event, most mild and resolving the same day. There were no serious treatment-emergent adverse events and no indication of increased suicidal ideation or behaviour.

Clinical Evidence

Goodwin, Croal, Feifel, Kelly, Marwood et al. (2023) · Neuropsychopharmacology

Population

19 adults with treatment-resistant depression, maintained on a concomitant SSRI

Intervention

Single 25 mg dose of COMP360 synthetic psilocybin with psychological support; 3-week follow-up

Comparator

None — open-label, no control or comparison arm

Finding

Mean MADRS change of −14.9 points (95% CI −20.7 to −9.2) at week 3; response and remission each in 42.1%; 63.2% had a mostly mild treatment-emergent adverse event; no serious TEAEs.

preliminary Nineteen participants, open-label, three weeks, no comparator. It establishes that meaningful improvement can occur without withdrawing the SSRI. It cannot establish how much benefit the SSRI cost.

Goodwin et al. (2023), Neuropsychopharmacology 48(10):1492–1499 (RTHM-01698)

This is where a lot of secondary coverage overreaches. You will frequently see this trial described as showing that psilocybin worked "but with attenuated effects compared to patients not on SSRIs." That comparison was never made. What the trial supports is narrower and still useful: for patients whose antidepressant withdrawal would be clinically problematic, this paradigm is worth testing properly.

The Safety Picture, Including the Part That Is Less Clean

The broadest safety analysis available is a 2024 systematic review by Halman and colleagues in the Journal of Psychopharmacology.^[3] After screening 7,102 records, the authors identified 52 studies from 36 reports published before September 2023: 32 on LSD, 10 on psilocybin, 4 on mescaline, 3 on DMT, 2 on 5-MeO-DMT and 1 on ayahuasca.

Their finding across that whole body of work: combining classic psychedelics with other drugs produced attenuated effects, potentiated effects, or no change depending on the pairing — and, except for a few case reports, no serious adverse drug events were described in the included studies.

That caveat matters and is usually dropped. It is also worth noticing how thin the psilocybin-specific evidence is: ten studies, across all drug classes, is not a large foundation for a confident safety claim about any single combination.

The real-world data adds texture. A 2024 content analysis by Sakai and colleagues in Psychopharmacology systematically searched Reddit for posts describing psilocybin mushroom and SSRI co-administration, identifying 443 eligible posts.^[4] The intensity findings match the survey: 54% described a reduced acute experience, while 39% reported unchanged intensity.

But 8% of posts described negative physical or psychological effects. Within those, 13 reports had features that may reflect serotonin toxicity, and one was concerning for a psychotic or manic episode.

443 Real-World Co-Use Reports

Two Different Questions, Two Different Answers

A systematic content analysis of Reddit posts describing psilocybin mushroom and SSRI co-administration. Intensity and adverse effects are shown separately because the study reports them as separate measures — they are not slices of one pie.

1 · How intense was the experience?

2 · Did anything go wrong?

This is the figure that keeps the “efficacy problem, not a safety problem” framing honest. The dominant signal really is reduced intensity. But a small number of these reports describe something that looks like serotonin toxicity, and a self-selected forum sample cannot tell you how often that happens per exposure. It is a reason to treat the combination as a supervised clinical question rather than a settled safe one.

Source: Sakai et al. (2024), Psychopharmacology 241(8):1617–1630 (RTHM-01979). Qualitative content analysis of 443 eligible Reddit posts. Not medical advice.

Safety Signal

Moderate

A small serotonin-toxicity signal sits underneath the reassuring headline

Concern

Among 443 real-world reports of psilocybin and SSRI co-use, 8% described negative physical or psychological effects, including 13 that may reflect serotonin toxicity and one concerning for a psychotic or manic episode. Forum reports cannot establish causation, cannot confirm what was taken, and have no denominator — but they are not nothing, and they are the only large real-world dataset that exists.

What the research says

Treat 'SSRIs are an efficacy problem, not a safety problem' as the best current summary rather than a settled fact. The controlled trial evidence is genuinely reassuring but consists of a handful of small studies. The authors of the Reddit analysis conclude that prospective studies are needed to evaluate whether psilocybin is reliably safe and effective in the setting of SSRI use.

Particularly relevant for: Anyone taking an SSRI or SNRI considering psilocybin, especially outside a supervised clinical setting

What to do

Know the warning signs of serotonin toxicity — agitation, confusion, rapid heart rate, high fever, muscle rigidity, tremor or twitching — and treat their sudden onset as an emergency requiring immediate medical care rather than something to wait out.

Sakai et al. (2024), Psychopharmacology 241(8):1617–1630 (RTHM-01979); Halman et al. (2024) (RTHM-01899)

It is worth contrasting this with the interaction that genuinely does look dangerous. An analysis of online experience reports found that 47% of 62 reports involving lithium plus a classic psychedelic described seizures, with a further 18% describing bad trips, and 39% involving medical attention — while none of 34 lamotrigine reports involved seizures.^[5] That is a different category of risk entirely, covered in Psilocybin and Lithium: The Dangerous Interaction.

The comparison is instructive precisely because both datasets are made of online reports. Same weak method, wildly different signal. With lithium it screams; with SSRIs it does not.

Why the Blunting Happens — and Why the Tidy Story Is Too Tidy

The standard explanation is 5-HT2A receptor downregulation, and it is a reasonable hypothesis rather than a demonstrated mechanism.

Psilocybin is converted in the body to psilocin, which acts largely by activating the serotonin 2A (5-HT2A) receptor in the cortex. SSRIs keep more serotonin available at the synapse. The proposal is that months of elevated serotonin lead the brain to reduce the number or sensitivity of 5-HT2A receptors as a compensatory adjustment, leaving psilocin with fewer targets — and that rebuilding that receptor population takes longer than clearing the drug, which would explain the long tail seen after discontinuation.

The story is coherent and it fits the fluoxetine sensitivity analysis well. But human imaging data does not support the simplest version of it. In a study of 16 healthy participants who had brain 5-HT2A receptor binding measured before a psilocybin session, higher cortical 5-HT2A binding was negatively associated with the duration of the peak plateau and negatively associated with mystical-experience scores.^[6] If more receptors straightforwardly meant a bigger experience, that is the opposite of what you would predict.

That does not overturn the downregulation hypothesis — a study of 16 healthy volunteers measuring baseline variation is answering a different question from what happens after chronic SSRI exposure. What it does mean is that anyone telling you the mechanism is settled is ahead of the evidence. The receptor-level relationship between 5-HT2A availability and subjective effect is not a simple dial.

Evidence Quality

1. Retrospective surveys and forum report analysescompleted

   Gukasyan 2023 (611 co-use and 1,542 post-discontinuation reports); Sakai 2024 (443 Reddit posts); Nayak 2021 (62 lithium reports, as contrast). Large numbers, weak instrument.

2. Small open-label clinical trialcurrent

   Goodwin 2023: 19 TRD patients kept on their SSRI, single 25 mg dose, 3-week follow-up, no comparison arm.

3. Randomised trial of psilocybin with vs. without a concurrent SSRImissing

   The study that would actually quantify how much effect the SSRI costs. Not yet done.

4. Pooled analysis across such trialsmissing

   Not possible until several controlled trials exist.

The interaction is well enough documented to plan around and too thinly studied to quantify. Everything strong about the evidence is observational; everything clinical is small and uncontrolled.

Gukasyan et al. (2023); Goodwin et al. (2023); Halman et al. (2024); Sakai et al. (2024)

What This Means If You Are on SSRIs

The SSRI-psilocybin interaction is not a contraindication in the way lithium appears to be. It is a trade-off, and the honest version has three parts.

First, expect a meaningful chance of a weaker experience — roughly half, based on the best available survey, with wide uncertainty around that number. Second, if you and your physician decide to taper, the timeline the data supports is longer than the two to four weeks usually quoted, and possibly much longer for someone who has been on an SSRI for years. Third, staying on the medication does not automatically make the attempt futile, though the trial evidence for that is nineteen people and three weeks.

Clinical programmes split on this. Some ask patients to taper before treatment, working with the prescriber over weeks. Others proceed while patients remain medicated, accepting a likely attenuated experience in exchange for psychiatric stability. The Goodwin trial is the reason the second approach is considered defensible enough to study further.

Critical Safety

Critical

Never stop an antidepressant abruptly in order to take psilocybin

Concern

Abruptly discontinuing an SSRI or SNRI can cause discontinuation symptoms — flu-like sensations, sleep disruption, irritability, dizziness, and the electrical sensations often called 'brain zaps' — and, more seriously, can precipitate a rapid return of the depression the medication was treating. Doing this unsupervised in order to hit a self-imposed washout deadline inverts the risk calculation: you would be trading a manageable reduction in psilocybin's intensity for a genuine destabilisation risk.

What the research says

Any change to an antidepressant is a medical decision made with the prescribing clinician, on a tapering schedule they set. If the timeline that emerges is incompatible with a planned psilocybin session, the session moves — not the taper.

Particularly relevant for: Anyone currently prescribed an SSRI or SNRI

What to do

Raise psilocybin with your prescriber directly rather than tapering first and disclosing later. If that conversation feels impossible, that is itself a signal to postpone.

Established clinical practice on antidepressant discontinuation; not a finding of the psilocybin studies cited in this article.

For how clinical protocols actually handle medication tapering before psilocybin therapy, see Should You Stop Medications Before Psilocybin? Clinical Guidance. For the full map of drug classes and how each interacts, see Psilocybin Drug Interactions: A Complete Guide. For serotonin syndrome specifically, see Psilocybin and Serotonin Syndrome: Real Risk or Overblown?. For microdosing-specific interaction data, see Microdosing Safety: What the Research Shows.

The Bottom Line

SSRIs and SNRIs blunt psilocybin's effects in a large share of users — 47% of SSRI reports and 55% of SNRI reports in a 2023 retrospective survey of 611 co-use reports, versus 29% for the non-serotonergic antidepressant bupropion. Across 1,542 post-discontinuation reports, the blunting rate did not drop significantly until the 3–6 month window, and removing long-half-life fluoxetine did not change that, suggesting something slower than drug clearance is involved. A 2023 open-label trial that kept 19 treatment-resistant depression patients on their SSRI still saw a mean 14.9-point MADRS improvement with no serious adverse events, though it had no comparison group and so cannot quantify what the SSRI cost. A 2024 systematic review found no serious adverse drug events across its included studies except in a few case reports, while a 443-post real-world analysis found 8% reporting negative effects, including 13 with possible serotonin toxicity. The best summary is that this is primarily a reduced-efficacy problem on a thin evidence base — not a demonstrated safety problem, and not a proven safe combination either.

Frequently Asked Questions

Do SSRIs block the effects of psilocybin?

They reduce them for many people rather than blocking them. In a 2023 retrospective survey of 611 co-use reports, 47% of SSRI reports described weaker-than-expected effects (95% CI 41–54%), as did 55% of SNRI reports. A separate analysis of 443 real-world reports found 54% describing reduced intensity but 39% describing unchanged intensity. So a substantial minority notice no difference at all. The leading explanation is downregulation of the 5-HT2A receptor that psilocybin acts on, though that mechanism is a hypothesis rather than a settled finding.

Can I take psilocybin if I'm on antidepressants?

That is a clinical decision for you and your prescriber, not something this article can answer. What the evidence shows is that a 2024 systematic review of drug interactions across classic psychedelics found no serious adverse drug events in its included studies apart from a few case reports, and that a 2023 trial safely administered psilocybin to 19 patients who stayed on their SSRIs. It also shows that real-world reports include a small number of cases with features suggesting serotonin toxicity. Do not stop antidepressants abruptly; discontinuation symptoms and relapse are genuine risks.

How long should I stop SSRIs before taking psilocybin?

Longer than the commonly quoted 2–4 weeks, based on the available data — but the honest answer is that nobody has established a correct number. In 1,542 reports from people who had stopped an antidepressant, the rate of blunted effects was statistically indistinguishable from the within-one-week rate until the 3–6 month window, when it fell to 30%. Removing fluoxetine, which has an unusually long half-life, did not change that. This suggests receptor-level recovery lags drug clearance. Any tapering schedule must be set by the prescribing physician.

Will psilocybin still work if I stay on my SSRI?

Possibly, based on limited evidence. In a 2023 open-label trial, 19 patients with treatment-resistant depression stayed on their SSRI, received a single 25 mg dose of psilocybin with psychological support, and showed a mean MADRS improvement of 14.9 points at three weeks, with response and remission each in 42.1%. Because there was no comparison group taking psilocybin without an SSRI, the trial cannot tell you how much benefit the medication cost you. It establishes that the combination is worth studying properly, not that it performs as well as psilocybin alone.

Is it dangerous to combine psilocybin with antidepressants?

For SSRIs and SNRIs, the documented risk is low but the evidence base is thin — only about ten psilocybin drug-interaction studies existed as of the 2024 systematic review, which reported no serious adverse drug events apart from a few case reports. A real-world analysis of 443 reports found 8% describing negative effects, including 13 with possible serotonin toxicity features. The clearly dangerous interaction in this space is lithium, where 47% of 62 online reports involved seizures. If you are on an antidepressant and unsure of its class, confirm with your prescriber before considering psilocybin.

Sources & References

1. 1RTHM-00827·Gukasyan, Natalie et al. (2023). “Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use..” Journal of psychopharmacology (Oxford.Study breakdown →PubMed →↩
2. 2RTHM-01698·Goodwin, Guy M et al. (2023). “Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication..” Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.Study breakdown →PubMed →↩
3. 3RTHM-01899·Halman, Andreas et al. (2024). “Drug-drug interactions involving classic psychedelics: A systematic review..” Journal of psychopharmacology (Oxford.Study breakdown →PubMed →↩
4. 4RTHM-00904·Sakai, Kimberly et al. (2024). “Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushrooms..” Psychopharmacology.Study breakdown →PubMed →↩
5. 5RTHM-01412·Nayak, Sandeep M et al. (2021). “Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports..” Pharmacopsychiatry.Study breakdown →PubMed →↩
6. 6RTHM-00720·Stenbæk, Dea Siggaard et al. (2021). “Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans..” Journal of psychopharmacology (Oxford.Study breakdown →PubMed →↩